Chronic hepatitis c patients non responding to therapy: Definitions of non response and treatment strategies;Malades atteints d'hépatite chronique C non répondeurs: Définitions de la non-réponse et stratégies thérapeutiques

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 8-9 C3, 2007, Pages

  Marcellin, Patrick ^a   Bourlière, Marc ^b   Pawlotsky, Jean Michel ^c   Ouzan, Denis ^d  

^a BEAUJON HOSPITAL   (France)

^b HÔPITAL SAINT JOSEPH   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d INSTITUT ARNAULT TZANCK   (France)

Author keywords

[No Author keywords available]

Indexed keywords

A 837093; ANTIVIRUS AGENT; BOCEPREVIR; ERYTHROPOIETIN; HCV 796; ITMN 191; MK 0608; PEGINTERFERON; PROTEINASE INHIBITOR; PSI 6130; R 1626; R 7128; RIBAVIRIN; SCHS 503034; UNCLASSIFIED DRUG; VALOPICITABINE; VX 950;

ALCOHOL CONSUMPTION; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; TREATMENT RESPONSE;

EID: 35948958254     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(07)92558-0     Document Type: Article

References (39)

1. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med 1997;127:875-81.
2. Maylin S, Martinot-Peignoux M, Ripault MP, Féray C, Nicolas-Chanoine MH, Marcellin P. Eradication du virus de l'hépatite C chez les malades atteints d'hépatite chronique C avec réponse virologique prolongée après traitement (Résumé). Clin Biol 2006;30 (Hors Série I):A102.
3. Conférence de Consensus : traitement de l'hépatite C. Gastroenterol Clin Biol 2002;26:B303-B311.
4. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7.
5. Schiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al.; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.
6. Ripault MP, Boyer N, Martinot M, Giuily N, Castelnau C, Pouteau M, et al. High efficacy of retreatment with pegylated interferon-ribavirin in patients with chronic hepatitis C, relapsers or non responders to interferon or interferon-ribavirin therapy. J Hepatol 2004 (abstract).
7. Moucari R, Ripault MP, Oulès V, Martinot-Peignoux M, Asselah T, Boyer N, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients nonresponders to standard combination therapy. J Hepatol 2007;46:596-604.
8. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-22.
9. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006;55:122-30.
10. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41.
11. Lang JP, Melin P, Ouzan D, Cattan L, Chousterman M, Rotily M, et al. A prospective, multicenter, observational study on adherence with viral hepatitis C treatments (CHEOBS) : impact of past psychiatric disorders on sustained virologic response (SVR) (abstract). J Hepatol 2007;46:S230.
12. Cacoub P, Ouzan D, Melin P, Lang JP, Rotily M, Fontanges T, et al. A prospective multicenter, observational study on compliance with viral hepatitis C treatments (CHEOBS study). Hepatology 2006;44:339.
13. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5:124-9.
14. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
15. Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol 2005;17:899-904.
16. Marcellin P, Freilich B, Andreone P, Brandao-Mello CE, Di Bisceglie A, Rai R, et al. Interim safety analysis of patients enrolled in the randomized, international retreatment with pegasys in patients not responding to prior peginterferon alfa-2B/ribavirin (RBV) combination therapy (REPEAT) study (abstract). Hepatology 2005;42:1174.
17. Curry M, Cardenas A, Afdhal NH. Effect of maintenance peg-interferon therapy on portal hypertension and its complication result from the COPILOT study (abstract). J Hepatol 2005;42:S40.
18. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human into cells in culture. Hepatology 1995;21:1003-10.
19. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.
20. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
21. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378-86.
22. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-5.
23. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
24. Alric L, Duffaut M, Selves J, Sandre K, Mularczyck M, Izopet J, et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol 2001;35:272-8.
25. Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D, et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001;48:843-8.
26. Nelson D, Rustgi V, Balan V, Subramanian M, Sulkowski M, J McHutchinson, et al. Sustained virologic response rates with albumin interferon alfa-2b in combination with ribavirin in non-responders to prior interferon therapy: interim results from a Phase 2 study (abstract). Hepatology 2006;44:A 611.
27. McHutchison J, Zeuzem S, Benhamou Y, Subramanian M. Interim antiviral and safety data with albumin interferon alfa-2b combined with ribavirin in a phase 2b study conducted in a genotype 1, IFN-naïve, chronic hepatitis C population. Hepatology 2006;44:A 615.
28. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005;25:72-83.
29. McHutchinson JG, Shiffman ML, Cheung RC, Gordon SC, Wright TL, Pottage JC, et al. A randomized, double-blind, placebo-controlled dose-escalationtrial of merimepodib (VX-497) and interferon alfa in previously untreated patients with chronic hepatitis C. Antiviral Ther 2005;10:635-43.
30. Marcellin P, Horsmans Y, Nevens F, Grange JD, Bronowicki JP, Vetter D, et al. Phase 2 study of the combination of merimepodib with peginterferon alfa-2b and ribavirin in non responders to previous therapy for chronic hepatitis C. J Hepatol 2007 (in press).
31. Benhamou Y, Pockros P, Rodriguez-Torres M, Gordon S, Shiffman M, Lurie Y, et al. The safety and efficacy of Viramidine® plus pegylated interferon alpha-2b versus ribavirin plus pegylated interferon alpha-2b in therapy naïve patients infected with HCV: phase 3 results (abstract). J Hepatol 2006;44:S273.
32. Marcellin P, Lurie Y, Rodrigues-Torres M, Chasen R, Xu Y, Murphy B. The safety and efficacy of taribavirin plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2a in therapy naive patients infected with HCV: phase 3 results. J Hepatol 2007;46(10):S7.
33. Asselah T, Marcellin P. BILN 2061: a major step toward new therapeutic strategies in hepatitis C. J Hepatol 2004;41:178-81.
34. Pawlotsky JM Treatment of hepatitis C: don't put all your eggs in one basket! Gastroenterology 2007;132:1611-5.
35. Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Brion N, Forestier N, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype 1 refractory to pegylated interferon (abstract). Hepatology 2005;42;A94.
36. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002.
37. Reesink HW, Forestier N, Weegink CJ, Zeuzem S, McNair L, Purdy S, et al. Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with pegylated interferon alfa 2a. J Hepatol 2006;44:S 272.
38. Lawitz E, Nguyen T, Younes Z, Santoro J, Gitlin N, McEniry D, et al. Valopicitabine (NM283) plus PEG interferon in treatment naïve hepatitis C patients with HCV genotype 1: HCV RNA clearance during 24 weeks of treatment (abstract). Hepatology 2006;44;A 223.
39. Roberts S, Cooksley G, Shaw D, Berns H.K, Brandt MT, Fettner SH, et al. 731 Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting hcv polymerase in chronic HCV patients J Hepatol 2006;44;S 269.